Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients with Multiple Myeloma

Description

This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM). The comprehensive geriatric assessment is a tool that can help to determine how fit a patient is. It is composed of a series of questions and tests designed for older people to evaluate their physical function, mental status, mental health, nutritional status, social support, level of social activity, and the presence of other medical problems. In addition to geriatric assessment domains, laboratory biomarkers may provide information on physiologic dysfunction as a measure for evaluation of frailty in the cancer setting. This study will help researchers in the future by predicting which patients will have more side effects with chemotherapy based on their comprehensive geriatric assessment and laboratory biomarkers, which will allow adjustments to treatment in older adult patients with MM.

Conditions

Plasma Cell Myeloma

Study Overview

Study Details

Study overview

This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM). The comprehensive geriatric assessment is a tool that can help to determine how fit a patient is. It is composed of a series of questions and tests designed for older people to evaluate their physical function, mental status, mental health, nutritional status, social support, level of social activity, and the presence of other medical problems. In addition to geriatric assessment domains, laboratory biomarkers may provide information on physiologic dysfunction as a measure for evaluation of frailty in the cancer setting. This study will help researchers in the future by predicting which patients will have more side effects with chemotherapy based on their comprehensive geriatric assessment and laboratory biomarkers, which will allow adjustments to treatment in older adult patients with MM.

The Role of the Comprehensive Geriatric Assessment in Elderly Patients with Multiple Myeloma: a Single Center Prospective Study

Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients with Multiple Myeloma

Condition
Plasma Cell Myeloma
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age \>= 65 years
  • * Diagnosis of MM based on International Myeloma Working Group (IMWG) diagnostic criteria
  • * Newly diagnosed or have received 1 prior line of treatment
  • * Planned to start a new treatment for MM within 30 days
  • * Transplant eligible or ineligible
  • * Fluent in English (all assessment tools are in English)
  • * Able to provide written informed consent
  • * Received \> 1 prior line of treatment
  • * Patients included in an interventional therapeutic trial
  • * Not able to give informed consent
  • * Severe mental or cognitive disorder precluding geriatric assessment

Ages Eligible for Study

65 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Shaji K. Kumar, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

2026-12-31